Lipidil (Fenofibrate)

Fenofibrate acts on lipid metabolism pathways to modify abnormal blood lipid levels.

• Hypertriglyceridemia: lowers elevated triglyceride concentrations.
• Mixed dyslipidemia: improves the overall lipid profile by reducing triglycerides and modestly increasing HDL‑cholesterol.
• Hypercholesterolemia: contributes to a reduction in LDL‑cholesterol when used as part of combination therapy.

• Fenofibrate activates peroxisome proliferator‑activated receptor alpha (PPARα), a nuclear transcription factor that up‑regulates genes involved in fatty‑acid oxidation, lipoprotein lipase activity, and clearance of triglyceride‑rich lipoproteins, resulting in decreased plasma triglycerides and modest improvements in HDL‑ and LDL‑cholesterol levels.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: transient increases in ALT/AST.
• Rash: mild skin irritation or pruritus.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with potential renal impairment.
• Acute liver injury: marked elevation of hepatic enzymes or jaundice.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Pancreatitis: acute inflammation of the pancreas.
• Hepatotoxicity: liver failure in predisposed individuals.
• Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

• Liver function monitoring: obtain baseline ALT/AST and repeat periodically.
• Renal function assessment: evaluate creatinine clearance, especially in elderly patients.
• Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness.
• Concomitant statin use: review dose and potential for myopathy.
• Severe hepatic impairment: avoid use in patients with established liver disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fenofibrate may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

• Gemfibrozil: markedly increases risk of rhabdomyolysis.
• Cyclosporine: elevates fenofibrate plasma concentrations.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely)

• Statins (especially high‑dose simvastatin or atorvastatin): increased myopathy risk.
• Bile‑acid sequestrants (e.g., cholestyramine): may reduce fenofibrate absorption.
• Oral contraceptives: potential alteration of lipid parameters; monitor efficacy.